VALARTH See Rubicon Research in the appOpen in app
RUBICON · NSE · Pharmaceuticals

Rubicon Research Ltd

What the numbers mean, from its filings and the exchange. Data as of 12 Oct 2026.
Small Cap · AMFI list Jan-Jun 2026
dear low confidence No valuation within 120 days; P/E 87.2 vs peers 37.5 (21st of 22); P/B 9.4 vs peers 5.4 (22nd of 25).
Statements through FY2026Prices adjusted for corporate actionsNot yet reviewed by the adversarial model

What is Rubicon Research's share price today?

Rubicon Research last traded at ₹1,540.20 on the NSE, as of 12 Oct 2026, 11:00 pm IST, down 0.5% on the day, up 146.5% over a year. Its 52-week range is ₹571 to ₹1,899. The live price is in the app.

₹1,540.20 −0.5% today
+146.5% over 1 year · NSE, as of 12 Oct 2026, 11:00 pm IST
12 month-end closes, 31 Oct 2025 to 30 Sep 2026, adjusted for splits and bonuses
52-week range73% of the way up
Low ₹571High ₹1,899

What is Rubicon Research's market cap?

Rubicon Research's market capitalisation is about ₹25,633 crore: what it would cost to buy every share at today's price. That makes it the 63rd largest small cap company we cover.

₹25,633 Cr Small Cap63rd largest small cap company
Small Cap means the companies ranked 251 and below by size, under SEBI's rules. Shares in issue are worked out from the market cap and the price. What market cap tells you →

Key facts

From the exchange
Symbol
NSE: RUBICON
ISIN
INE506V01022
Cap bucket
Small Cap, 63rd largest by market cap
Industry (NSE)
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Listed since
2025
Futures and options
Not traded

Is Rubicon Research overvalued?

Dear, with low confidence: no valuation within 120 days; P/E 87.2 vs peers 37.5 (21st of 22); P/B 9.4 vs peers 5.4 (22nd of 25).

Valuation

Latest price and trailing 12 months
P/E 87.19
vs peers 37.5 · 21st of 22
Price divided by last year's earnings per share: how many years of today's profit you pay for. Learn more →
P/B 9.42
vs peers 5.4 · 22nd of 25
Price divided by book value per share: what you pay for each rupee of net assets on the balance sheet. Learn more →
Market cap ₹25,633 Cr
Total market value of all shares, in ₹ crore. Learn more →
Dividend yield 0.2%
vs peers 0.6% · 14th of 16
Last year's dividends as a share of today's price. Learn more →
PEG (vendor) 11.16
vs peers 2.8 · 15th of 17
P/E divided by the vendor's earnings growth figure, which it does not disclose; a P/E adjusted for how fast profits grow. Learn more →
PEG on our 3-year EPS growth Not available
P/E divided by the 3-year EPS growth rate from the stored accounts. Learn more →
2 models could be judged
Skipped — Fair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored; P/E vs own history: 0 of 36 months of P/E history

Our valuation range

🔒 Pro
Value range, implied growth at today's price, and the nine models behind it: in the app.

Is Rubicon Research a quality business?

Quality score 44.8, 16th of 24 in its peer set; WATCH on 28 of 30 flags judged.

Quality and risk

Data as of 12 Oct 2026
Business quality Not available
The kind of business, which sets the yardstick it is judged by. Learn more →
Quality score 44.8
vs peers 53.5 · 16th of 24
Returns, margins, leverage and consistency against its peers, out of 100. Learn more →
Risk level WATCH
28 of 30 flags judged
From flags on debt, earnings quality, dilution and price swings. Learn more →

Profitability

ROE 18.6%
vs peers 15.7% · 9th of 25
Return on equity: profit as a share of shareholders' money. Learn more →
ROCE 20.8%
vs peers 19.1% · 12th of 25
Return on capital employed: operating profit as a share of all the capital in the business, debt and equity. Learn more →
Profit margin 14.8%
vs peers 15.8% · 14th of 24
Profit after everything, as a share of revenue. Learn more →
EPS ₹14.95
Trailing 12 months
Profit for each share over the last 12 months.

Scorecard

🔒 Pro
Health scores and red flags with their values and history: in the app.
See the scorecard →
Inside the app

Get a sneak peek of Valarth

Start freeStart free
A Valarth stock page: the share price with its chart and 52-week range, valuation and profitability figures, and a scorecard of health checks.
Stock pagePrice, valuation, profitability and a scorecard of health checks for every company, each figure explained.
The Valarth stock screener: a table of companies with price, market cap, P/E, P/B, PEG, EPS and ROE, and filters down the left.
ScreenerEvery listed company, filtered on 212 figures, each with a plain-language lesson beside it.
The Valarth AI Screener answering 'Which companies will benefit from India's Project 75 submarine programme?' with a basket of four naval shipbuilders and a written thesis.
AI ScreenerAsk a question in plain English, like which companies benefit from India's Project 75. It reads the intent, builds the screen and writes the thesis.
A Valarth business-model card for State Bank of India, with a plain-language summary and statements verified against the filing.
Business modelHow a company makes money and what can hurt it, each statement checked against its annual report.
Valarth's Before the Bell edition, with the day's headline, regulator notes and sector moves.
Before the BellA morning edition before the market opens: what moved, which rule changed, and what it means for your holdings.

Has Rubicon Research made money for shareholders?

Yes: +146.5% over one year.

Shareholder returns

1-year return +146.5%
Price only
What the share price did over the last 12 months. Learn more →
5-year return Not available
Yearly average price return over five years, bonuses and splits adjusted. Learn more →
Wealth destroyer Not available
Five-year total return — price CAGR on bonus- and split-adjusted closes plus the dividend yield — below the 7% a bank fixed deposit paid. Learn more →

Returns

3Y and 5Y are yearly averages
1W
−3.7%
1M
−14.7%
3M
+7.7%
6M
+88.9%
1Y
+146.5%
3Y
—
5Y
—
— not available

Does Rubicon Research pay a dividend?

Yes. Rubicon Research's dividend yield is 0.19% at the latest price; the last payout was ₹1.50 a share, ex-dividend 7 Aug 2026.

Dividends

Per share, by ex-dividend date
Dividend yield0.19%
The past 12 months' dividends as a share of today's price.
7 Aug 2026 · Final₹1.50
Payout ratio🔒 In the app
The share of profit paid out as dividends; a very high share leaves little to reinvest.
Dividend growth, 5 years🔒 In the app
How fast the dividend per share has grown a year.
Years without a miss🔒 In the app
How many years in a row a dividend has been paid.

Is Rubicon Research growing?

Revenue 3 years 61.4% a year; revenue 5 years 42.6% a year; eps 5 years 50.3% a year.

Growth

Statements through FY2026 (Mar-26)
Revenue 3 years 61.4% a year
vs peers 14.8% · 2nd of 24
Compound annual growth of revenue over three years. Learn more →
Profit 3 years Not available
Compound annual growth of net profit over three years. Learn more →
Revenue 5 years 42.6% a year
Compound annual growth of revenue over five years. Learn more →
Profit 5 years Not available
Compound annual growth of net profit over five years. Learn more →
EPS 3 years Not available
Growth in earnings per share, so dilution counts against the company. Learn more →
EPS 5 years 50.3% a year
Growth in earnings per share over five years, so dilution counts against the company. Learn more →
P/E vs own history Not available
Today's P/E against its own 5-year median; negative is cheaper than its history. Learn more →

How did Rubicon Research do last quarter?

Rubicon Research reported revenue of ₹534 Cr, up 36.6% on a year earlier and a net profit of ₹85 Cr, up 83.6% in the Jun 2026 quarter.

Latest quarter

Jun 2026
Revenue, latest quarter₹534 Cr
+36.6% on a year earlier
What the company took in over the quarter.
Net profit, latest quarter₹85 Cr
+83.6% on a year earlier
What was left for shareholders after every cost and tax.

How does Rubicon Research compare with its peers?

Compared with 24 Pharmaceuticals; 21st of 22 on P/E; 16th of 24 on quality score.

Compared with 24 Pharmaceuticals

24 companies

Rubicon Research against its peers

Largest 10 of 24 peers, by market cap
CompanyMarket capP/EP/BROEROCE1YQuality 🔒Rank 🔒
Rubicon Research Ltd₹25,633 Cr87.29.418.6%20.8%+146.5%
Ipca Laboratories Ltd₹48,595 Cr36.05.115.2%19.5%+44.7%
Glaxosmithkline Pharmaceuticals Ltd₹43,034 Cr41.017.348.3%58.2%−7.6%
Ajanta Pharma Ltd₹42,612 Cr37.58.324.1%30.6%+41.0%
J B Chemicals & Pharmaceuticals Ltd₹38,677 Cr—8.218.2%24.2%+45.1%
Emcure Pharmaceuticals Ltd₹34,783 Cr34.48.221.8%22.8%+33.8%
Wockhardt Ltd₹32,440 Cr79.26.29.9%9.6%+43.8%
Sai Life Sciences Ltd₹31,606 Cr86.78.214.6%18.7%+71.4%
Neuland Laboratories Ltd₹26,802 Cr53.88.321.5%26.5%+28.0%
Piramal Pharma Ltd₹26,212 Cr—2.29.0%10.8%−0.3%
Acutaas Chemicals Ltd₹25,876 Cr67.012.624.6%32.7%+110.9%
Peer median—37.55.415.7%19.1%+25.3%
Market cap in rupees crore; P/E and P/B on the latest price; 1Y is the price return over a year. A dash is a figure that does not apply or is not reported.

Full peer comparison

🔒 Pro
Every peer, every figure, the ranks and the quality and forensic scores side by side: in the app.

Who owns Rubicon Research?

Rubicon Research is held by promoters 59.8%, foreign institutions 7.5%, domestic institutions 9.4%.

Shareholding pattern

Latest filing, percent of shares
Promoters59.8%
The founders and controlling group.
Foreign institutions7.5%
Overseas funds investing through the FPI route.
Domestic institutions9.4%
Indian insurers, banks, pension and mutual funds together.
Mutual funds7.2%
Indian mutual fund schemes; part of domestic institutions.
Retail and others3.2%
Individual investors and everyone else.
Promoter shares pledged🔒 In the app
Promoter shares given as collateral for loans; a high share is a risk to watch.
Holding trend🔒 In the app
Whether promoters, foreign funds and mutual funds have been adding or selling over recent quarters.

What do analysts say about Rubicon Research?

2 analysts cover Rubicon Research, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Analyst consensus

2 analysts
ConsensusBuy
The rating most covering analysts give the share.
Average target price🔒 In the app
The mean of the analysts' 12-month price targets.
Upside to target🔒 In the app
How far the target sits above or below today's price.
Share rating it a buy🔒 In the app
The share of covering analysts with a buy rating.

What does Rubicon Research do and what is it sensitive to?

Rubicon Research describes itself as an R&D driven, formulations manufacturing and marketing company focused on regulated markets, selling specialty products, drug-device combinations and complex generics. Sensitive to: INR depreciation against USD.

Business-model card

FY2026 · 33 verified
5Revenue
3Channels
1Regulators
4Reg. dependencies
4Sensitivities
3Costs
3Geographies

Rubicon Research describes itself as an R&D driven, formulations manufacturing and marketing company focused on regulated markets, selling specialty products, drug-device combinations and complex generics. Its US sales run through wholly owned subsidiaries to wholesalers, group purchasing organizations and pharmacy chains, and it earns from product sales at a gross margin shown in its income statement.

Revenue engine

5 verified
Specialty products (26.9%)
Interpretation: the company reports specialty products as a gross-margin contributor, with the 26.92% share stated against total gross margin, not revenue.
Specialty portfolio contribution to gross profit in Q2 (32.5%)
Company states the specialty portfolio's share of gross profit for the quarter, a gross-profit measure rather than revenue.
Generic ANDA products
Interpretation: the company holds ANDA approvals, which are the basis for its generic product sales; the excerpt states the number of approvals, not revenue.
2 more statements
Own ANDA revenues
Company describes its 2014-21 stage as earning own ANDA revenues, selling through a third-party distributor at that time.
Drug-device combinations (intra-nasal sprays)
Company lists drug-device combinations from 2023 onwards, with intra-nasal sprays named as the product type.

Customers & channels

3 verified
Subsidiary US sales and marketing companies
Subsidiary US sales companies market non-branded prescription products to wholesalers, group purchasing organizations and pharmacy chains.
Subsidiary Validus: branded prescription products
Subsidiary Validus is the sales and marketing platform for the company's branded prescription products.
Direct customer relationships
Interpretation: from 2022 the company moved to direct customer relationships, replacing sales through a third-party distributor.

Regulators

1 verified
US FDA (USFDA)
Governs the company's manufacturing site inspections and product review; the company states its Ambernath and Satara sites have been inspected by regulators including USFDA.

Regulatory dependencies

4 verified
Absence of substitutable US generics for three brands
Interpretation: where no FDA-approved substitutable generic exists, competition on the three branded products is limited, so a change in generic approvals would move branded revenue.
USFDA inspection and EIR status of manufacturing site
Interpretation: an FDA inspection outcome (EIR) gates the site's ability to supply product, so an adverse inspection would affect manufacturing and revenue.
Pithampur site inspection history
Interpretation: the Pithampur site, which the company says will be operationalised in mid CY2026, was previously inspected by USFDA, so its regulatory status affects when added capacity can supply product.
1 more statement
Product approvals
Interpretation: approvals add products that can then be commercialised, so approval timing moves the product count and revenue.

Sensitivities

4 verified
INR depreciation against USD
Company states INR depreciation had only a marginal sequential effect on EBITDA because costs are USD denominated and hedges incurred MTM losses; Interpretation: a weaker INR raises INR-reported revenue but its EBITDA effect is partly offset by USD costs.
USD denomination of revenue
Interpretation: nearly all revenue is USD denominated, so reported INR revenue moves with the USD/INR rate.
Reliance on outsourced manufacturing
Interpretation: if revenue traction exceeds plan, more volume goes to outsourced manufacturing, which the company says could lower gross margin further.
1 more statement
Pricing
Company states pricing remained stable, which it attributes to its focus on specialty and differentiated products; a shift toward commoditised pricing would reduce margin.

Cost inputs

3 verified
Outsourced manufacturing
Driver: own manufacturing capacity constraints in select dosage forms; the company says revenue from outsourced manufacturing increased as a result.
R&D expense (11.0%)
Company states R&D expense as a share of operating revenue and expects it to stay at an industry leading 10-11% of revenue; it is fully expensed in the P&L.
Fully expensed R&D policy
Company states R&D is fully expensed in the P&L as a continuing policy, so R&D spend reduces reported profit in the period incurred.

Geographies

3 verified
United States marketing
Company has an established marketing, sales and distribution platform in the US, run through subsidiaries.
Thane, India R&D facility
R&D facility in Thane, India, with multiple dosage form laboratories.
Ontario, Canada nasal and inhalation centre
R&D centre in Ontario focused on nasal and inhalation products and drug-device combinations.
Each statement is checked word for word against the FY2026 annual report; the passages are in the app.

What changed recently?

Q1 FY2027 results filed (14 Aug 2026).

Change log

5 entries · newest first
  1. Results filedQ1 FY2027 results filed.
  2. Corporate actionDividend - Rs 1.50 Per Share.
  3. Results filedQ4 FY2026 results filed.
  4. Results filedQ3 FY2026 results filed.
  5. Results filedQ2 FY2026 results filed.
Get alerts →Sign in to be told when any of these change.

What this page does not tell you

What could not be judged, and why. Never empty.
  • Models not runFair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored; P/E vs own history: 0 of 36 months of P/E history.
  • FlagsWATCH on 28 of 30 flags judged; 1 red; 2 could not be judged.
  • Data gapsPEG on our 3-year EPS growth, Business quality, 5-year return, Wealth destroyer, Profit 3 years, Profit 5 years and 2 more: not available yet.

What this page rests on

✓7 years of annual statements, through FY2026 (Mar-26)✓9 quarters of results✓12 months of month-end prices, adjusted for bonuses and splits○no valuation of ours yet✓business-model card FY2026 · 33 verified

Questions people ask

What is Rubicon Research's share price today?

Rubicon Research last traded at ₹1,540.20 on the NSE, as of 12 Oct 2026, 11:00 pm IST, down 0.5% on the day, up 146.5% over a year. Its 52-week range is ₹571 to ₹1,899. The live price is in the app.

What is Rubicon Research's market cap?

Rubicon Research's market capitalisation is about ₹25,633 crore: what it would cost to buy every share at today's price. That makes it the 63rd largest small cap company we cover.

Is Rubicon Research Ltd a large cap, mid cap or small cap?

Rubicon Research Ltd (RUBICON) is a small cap company in AMFI's classification for Jan-Jun 2026. SEBI's buckets go by rank on six-month average market capitalisation: the top 100 are large caps, 101 to 250 mid caps, the rest small caps.

What is Rubicon Research Ltd's P/E ratio?

87.19, vs peers 37.5 · 21st of 22. Price divided by last year's earnings per share: how many years of today's profit you pay for.

Is Rubicon Research Ltd overvalued?

Dear, with low confidence: no valuation within 120 days; P/E 87.2 vs peers 37.5 (21st of 22); P/B 9.4 vs peers 5.4 (22nd of 25).

How does Rubicon Research Ltd make money?

Rubicon Research describes itself as an R&D driven, formulations manufacturing and marketing company focused on regulated markets, selling specialty products, drug-device combinations and complex generics. Its US sales run through wholly owned subsidiaries to wholesalers, group purchasing organizations and pharmacy chains, and it earns from product sales at a gross margin shown in its income statement.

Who are Rubicon Research Ltd's peers?

Compared with 24 Pharmaceuticals: Ipca Laboratories Ltd, Glaxosmithkline Pharmaceuticals Ltd, Ajanta Pharma Ltd, J B Chemicals & Pharmaceuticals Ltd, Emcure Pharmaceuticals Ltd and 19 more. The app shows how they compare on every figure.

Is this investment advice?

No. Valarth is a research and learning tool and is not a SEBI-registered investment adviser or research analyst. The figures come from the company's filings and the exchanges; what to do with them is your call.

How did Rubicon Research do last quarter?

Rubicon Research reported revenue of ₹534 Cr, up 36.6% on a year earlier and a net profit of ₹85 Cr, up 83.6% in the Jun 2026 quarter.

Who owns Rubicon Research?

Rubicon Research is held by promoters 59.8%, foreign institutions 7.5%, domestic institutions 9.4%.

Does Rubicon Research pay a dividend?

Yes. Rubicon Research's dividend yield is 0.19% at the latest price; the last payout was ₹1.50 a share, ex-dividend 7 Aug 2026.

What do analysts say about Rubicon Research?

2 analysts cover Rubicon Research, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Everything on Rubicon Research, and 6,621 other companies, with 212 filters and the full peer tables

See Rubicon Research in the app →See pricing